IP Library Granted Patent US 10,870,705
Granted Patent B2
US 10,870,705 · App. 15/537,780 · Granted Dec 22, 2020

Chimeric antigen receptors specific for carbonic acid anhydrase IX

Inventor: Wayne A. Marasco (Wellesley, MA)
Assignee: DANA-FARBER CANCER INSTITUTE, INC.
C07K16/30A61K35/17A61K38/2013A61K39/0011C07K14/7051C07K14/70521C07K16/40C12N5/0637C12N5/0638C12N9/88C12Y402/01001A61K2039/505C07K2317/51C07K2317/515C07K2317/565C07K2317/60C07K2317/622C07K2319/03C07K2319/33C07K2319/74C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,870,705
App. No.
15/537,780
Granted
Dec 22, 2020
Kind
B2
Abstract

The present invention provides chimeric antigen receptor cells specific for carbonic anhydrase IX (CAIX) and methods of using same for treatment of CAIX expressing cancers such as renal cell carcinoma.

Claims (12)

1. A chimeric antigen receptor (CAR) comprising an intracellular signaling domain, a transmembrane domain and an extracellular domain, wherein the extracellular domain comprises comprising a carbonic-anhydrase-IX (G250)-specific antibody or fragment thereof, wherein the intracellular signaling domain comprises a CD3 zeta chain.

2. The CAR of claim 1 , wherein the transmembrane domain further comprises a stalk region positioned between the extracellular domain and the transmembrane domain.

3. The CAR of claim 1 , wherein the transmembrane domain comprises CD28.

4. The CAR of claim 1 , further comprising one or more addition costimulatory molecules positioned between the transmembrane domain and the intracellular signaling domain.

5. The CAR of claim 4 , wherein the costimulatory molecules is CD28, 4-1BB, Inducible T cell costimulator (ICOS), or OX40.

6. The CAR of claim 1 , wherein the antibody is an Fab or scFV.

7. The CAR of claim 1 , wherein the antibody comprises (a) a heavy chain comprising

a CDR1 comprising an amino acid sequence SYAMS (SEQ ID NO: 55);

a CDR2 comprising an amino acid sequence AISANGGTTYYADSVKG (SEQ ID NO: 67); and

a CDR3 comprising an amino acid sequence NGNYRGAFDI (SEQ ID NO: 65); and (b)

a light chain with a CDR1 comprising an amino acid sequence TGSSSNIGAGFDVH (SEQ ID NO: 68), an amino acid sequence TGSSSNIGAGYDVH (SEQ ID NO: 61), or an amino acid sequence TGTSSNIGAGYDVH (SEQ ID NO: 81); a CDR2 comprising an amino acid sequence GNTNRPS (SEQ ID NO: 69), an amino acid sequence GNSNRPS (SEQ ID NO: 72), or an amino acid sequence GNNNRPS (SEQ ID NO: 62); and a CDR3 comprising an amino acid sequence QSYDSRLSAWV (SEQ ID NO: 70), an amino acid sequence QSYDRSLSWV (SEQ ID NO: 73), an amino acid sequence QSYDSTLRVWM (SEQ ID NO: 74), an amino acid sequence QSYDKSLTWV (SEQ ID NO: 76), an amino acid sequence QSYDKSLSWV (SEQ ID NO: 80), or an amino acid sequence QSYDSSLSAWV (SEQ ID NO: 82).

8. The CAR of claim 6 , wherein the scFv antibody has a heavy chain comprising an amino acid sequence selected from the group consisting of the amino acid sequences of SEQ ID NOs 1, 3-23, and wherein said scFv antibody has a light chain comprising an amino acid sequence selected from the group consisting of the amino acid sequences of SEQ ID NOs: 2 and 24-44.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2017
From: MARASCO, WAYNE A.
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 044457/0759 →
Continuity (2)
Provisional Application 62094596 · Dec 19, 2014
Related Publication 20180030147A1 · Feb 1, 2018
Cited By (2)
US 12,257,304 US 12,686,714